Abbott Laboratories Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Abbott Laboratories on February 20, 2026. The report addresses a corporate governance amendment regarding the composition of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statement data.
Material Changes
On February 20, 2026, the Board of Directors amended Article III, Section 2 of the Company's By-Laws. The amendment reduces the number of directors from thirteen to twelve. This change is effective as of April 24, 2026.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is limited to the procedural amendment of the By-Laws.
Investor Verification Checklist
- Verify the effective date of the Board size reduction (April 24, 2026).
- Confirm the new total number of directors (twelve).
- Review the attached Exhibit 3.1 for the full text of the amended By-Laws.